PJP Performance — Invesco Pharmaceuticals ETF
Data updated: 2026-09-28
PJP returned +16.75% year to date and +51.60% over one year to Jul 2026. Annualised returns are +17.15% over 3 years and +9.49% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $161, against $137 for the category, and to $152 over one year, against $137. Volatility over the past three years was 14.75% a year. In the 12 months to Jul 2026 the fund took in a net $118.3M, and assets reached $472.10M.
PJP Growth of $100
What $100 invested in Invesco Pharmaceuticals ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | PJP | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $152 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $161 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $157 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $226 | $183 |
PJP Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +16.75% |
| 1 year | +51.60% |
| 3 years (annualised) | +17.15% |
| 5 years (annualised) | +9.49% |
PJP Annual Returns
Calendar-year total returns of Invesco Pharmaceuticals ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +16.75% |
| 2025 | +27.91% |
| 2024 | +9.72% |
| 2023 | −2.22% |
| 2022 | −2.04% |
| 2021 | +14.45% |
| 2020 | +11.17% |
| 2019 (Aug–Dec) | +13.34% |
PJP Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.7% | +3.0% | −3.9% | +1.2% | +4.4% | +8.1% | +2.6% | — | — | — | — | — |
| 2025 | +4.1% | +0.9% | 0.0% | −5.2% | −2.6% | +0.4% | +1.2% | +12.7% | +1.8% | +4.6% | +9.6% | −1.2% |
| 2024 | −0.4% | +1.5% | +4.6% | −3.8% | +3.2% | +3.5% | +4.4% | +4.0% | −2.3% | −0.7% | +0.8% | −4.9% |
| 2023 | −0.1% | −3.2% | +0.3% | +2.0% | −4.0% | +1.8% | +3.0% | −0.3% | −6.6% | −4.7% | +2.6% | +7.7% |
| 2022 | −4.6% | −2.0% | +5.3% | −4.5% | −0.4% | −0.6% | +0.6% | −5.1% | −0.3% | +7.4% | +5.0% | −1.9% |
| 2021 | +8.4% | −1.0% | +3.1% | −0.9% | +0.6% | +2.6% | +0.9% | +1.1% | −5.6% | +2.3% | −2.2% | +4.9% |
| 2020 | −3.4% | −6.9% | −5.3% | +13.6% | +3.7% | +0.2% | +0.3% | +1.1% | −2.7% | −2.6% | +7.4% | +7.1% |
| 2019 | — | — | — | — | — | — | — | −2.4% | +1.4% | +5.4% | +6.6% | +1.9% |
PJP Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 14.75%
- 3-year Sharpe ratio: 0.86 (vs 4.5% risk-free rate)
- Best month: +12.69% (Aug 2025)
- Worst month: −6.57% (Sep 2023)
PJP Fund Flows
Monthly money in and out of Invesco Pharmaceuticals ETF, from SEC Form N-PORT.
- 12-month net flow: $118.3M
- 12-month gross sales (incl. reinvestments): $240.7M
- Sales ÷ redemptions: 1.97×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $104.0M | $0 | $104.0M |
| Jun 2026 | $0 | $11.4M | −$11.4M |
| May 2026 | $0 | $6.3M | −$6.3M |
| Apr 2026 | $0 | $70.6M | −$70.6M |
| Mar 2026 | $2.1M | $4.1M | −$2.0M |
| Feb 2026 | $9.8M | $5.4M | $4.5M |
| Jan 2026 | $107.5M | $22.0M | $85.6M |
| Dec 2025 | $7.4M | $0 | $7.4M |
| Nov 2025 | $8.0M | $0 | $8.0M |
| Oct 2025 | $0 | $0 | $0 |
| Sep 2025 | $912K | $911K | $726 |
| Aug 2025 | $823K | $1.7M | −$904K |
PJP Assets Under Management
Net assets of Invesco Pharmaceuticals ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $472.10M |
| 2026-04-30 | $333.09M |
| 2026-01-31 | $402.14M |
| 2025-10-31 | $276.94M |
| 2025-07-31 | $232.15M |
| 2025-04-30 | $243.74M |
| 2025-01-31 | $265.05M |
| 2024-10-31 | $280.77M |
| 2024-07-31 | $284.91M |
| 2024-04-30 | $264.04M |
| 2024-01-31 | $273.41M |
| 2023-10-31 | $244.97M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.